STAT6

Nurix Therapeutics Announces Extension of Strategic Collaboration with Sanofi to Develop Novel Targeted Protein Degraders of STAT6

Retrieved on: 
Tuesday, April 9, 2024
Autoimmunity, Inflammation, Patient, SAN, STAT6, Cancer, Therapy, IRAK4, BTK

SAN FRANCISCO, April 09, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, announced today an extension of the ongoing research program with Sanofi for STAT6 (signal transducer and activator of transcription 6). STAT6 is a key drug target in type 2 inflammation.

Key Points: 
  • “STAT6 is a key transcription factor within the IL-4/IL-13 signaling pathways which act as drivers of inflammation in allergic conditions.
  • “Preclinical data from our STAT6 degraders show that targeted degradation of this key transcription factor provides a rapidly acting and potent blockade of signaling.
  • “We are very excited to pursue our collaboration with Sanofi, as it further demonstrates the productivity of our long-standing research program to develop a pipeline of breakthrough degraders to treat inflammation and autoimmunity.
  • Nurix’s disclosed pipeline in inflammation and autoimmunity now includes the STAT6 degrader with Sanofi, the IRAK4 degrader with Gilead, and Nurix’s proprietary BTK degrader, NX-5948.

Kymera Therapeutics Presents Preclinical Data for STAT6 and TYK2 First-In-Class, Oral Degrader Immunology Programs at the American Academy of Dermatology Annual Meeting

Retrieved on: 
Friday, March 8, 2024
Janus, Model, Spleen, STAT6, Doctor of Philosophy, Inflammation, Atopic dermatitis, Immunoglobulin E, Resource, JAK, Therapy, Inflammatory bowel disease, Protein, TYK2, TPD, Stem cell, Biology, Serum, Phase 1, American Academy, Pharmaceutical industry

WATERTOWN, Mass., March 08, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced that its preclinical data demonstrating the therapeutic potential of its potent and selective heterobifunctional degraders of STAT6 (KT-621) and TYK2 (KT-294) are being presented in the poster session at the American Academy of Dermatology’s Annual Meeting in San Diego, California. Kymera’s oral STAT6 and TYK2 degraders have the potential to address multiple immune-mediated diseases and overcome the limitations of existing technologies and agents. Today’s poster presentations mark the first time that data from a STAT6 targeted agent and a TYK2 degrader have been shared at a major medical meeting. Based on the results generated to date, Kymera intends to initiate Phase 1 testing for KT-621 and KT-294 in the in the second half of 2024 and the first half of 2025, respectively. Data from both Phase 1 trials are expected to be reported in 2025.

Key Points: 
  • Kymera’s oral STAT6 and TYK2 degraders have the potential to address multiple immune-mediated diseases and overcome the limitations of existing technologies and agents.
  • Today’s poster presentations mark the first time that data from a STAT6 targeted agent and a TYK2 degrader have been shared at a major medical meeting.
  • “Our differentiated strategy to targeted protein degradation has resulted in an industry-leading immunology pipeline of oral degrader medicines, each with the potential to treat multiple complex immuno-inflammatory diseases.
  • At low daily oral doses, preclinical studies with KT-621 demonstrated near full in vivo STAT6 degradation in disease-relevant tissues that was well-tolerated.

Kymera Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update

Retrieved on: 
Thursday, February 22, 2024
Well, Janus, International, Neoplasm, Psoriasis, STAT6, Research, Toxicity, AML, Doctor of Philosophy, ASH, Investment, Blood, Atopic dermatitis, Cash, Growth, Janus kinase, Sale, Lupus, Skin, CTCL, PD-1, Inflammation, Society, JAK, Biomarker, Therapy, Immunology, Hidradenitis suppurativa, Administration, Webcast, Inflammatory bowel disease, Patient, Autoimmunity, Arm, Lymphoma, TYK2, Clinical trial, HS, TPD, G&A, Development, Dupilumab, Phase 1, Human, Pharmaceutical industry

Under the terms of the Sanofi/Kymera collaboration, the dosing of the first patients generated milestone payments totaling $55 million.

Key Points: 
  • Under the terms of the Sanofi/Kymera collaboration, the dosing of the first patients generated milestone payments totaling $55 million.
  • Enrollment in both trials is ongoing, with topline data expected to be reported in the first half of 2025.
  • Kymera unveiled its first-in-class oral STAT6 degrader, KT-621, at its Immunology R&D Day in January.
  • To access the conference call via phone, please dial +1 (833) 630-2127 or +1 (412) 317-1846 (International) and ask to join the Kymera Therapeutics call.

Kymera Therapeutics Outlines Key 2024 Objectives and Strategy to Progress Leading Portfolio of Immunology and Oncology Programs

Retrieved on: 
Tuesday, January 9, 2024
Well, Janus, STAT3, Patient, Janus kinase, Lymphoma, Therapy, Lupus, ALL, TPD, Asthma, Hematology, STAT6, JAK, Roflumilast, Inflammatory bowel disease, Society, HS, Cancer, Bone marrow, Arm, Q&A, Acute leukemia, IND, MDM2, Autoimmunity, Conference, Interim, Inflammation, TYK2, Psoriasis, Toxicity, Webcast, Clinical trial, File, Atopic dermatitis, Blood, Pharmaceutical industry

ET

Key Points: 
  • ET
    WATERTOWN, Mass., Jan. 09, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced its corporate goals for 2024, including anticipated progress on its best-in-class pipeline of immunology and oncology programs.
  • Sanofi, which is collaborating with Kymera on the development of KT-474 outside of the oncology and immune-oncology fields, is conducting the Phase 2 studies.
  • KT-621 has potentially broad utility across a number of allergic diseases, including atopic dermatitis, asthma and chronic obstructive pulmonary disorder, among others.
  • Kymera is working to develop a biomarker-based patient selection strategy for subsequent development beyond Phase 1a.

R&D Day Highlights Kymera’s Immunology Strategy and Emerging Pipeline of Novel, First-in-Class Oral Degraders Addressing Multiple Highly Prevalent Immuno-inflammatory Diseases

Retrieved on: 
Thursday, January 4, 2024
Janus, Atopic dermatitis, Receptor (biochemistry), Sanofi, Janus kinase, Hidradenitis suppurativa, Eosinophilic esophagitis, Autoimmunity, Inflammatory bowel disease, HS, Inflammation, Lupus, Blood, TLR, Therapy, Clinical trial, Asthma, JAK, Dupilumab, Roflumilast, Polyp (medicine), TPD, Webcast, Patient, Psoriasis, TYK2, STAT6, Skin, Sinusitis, Pharmaceutical industry

As part of its strategy, Kymera is unveiling two new programs that each have the potential to address multiple immune-mediated diseases, each with considerable market potential.

Key Points: 
  • As part of its strategy, Kymera is unveiling two new programs that each have the potential to address multiple immune-mediated diseases, each with considerable market potential.
  • Kymera will share its immunology strategy, including market insights, program updates, new preclinical data and development timelines, at its virtual R&D Day this morning.
  • In addition, at low oral doses, KT-621 demonstrated near full in vivo STAT6 degradation and was well-tolerated in multiple preclinical toxicity studies.
  • Kymera will host a webcast to discuss its emerging immunology pipeline from 10:00 a.m. – 12:00 p.m.

New Insights Revealed On Tissue-Dependent Roles of JAK Signaling in Inflammation

Retrieved on: 
Thursday, December 21, 2023
Biology, MTR, Dermatitis, DOI, Hospital, Atopic dermatitis, Protein, FAAD, Family, Immune system, Division, Neuron, Sensation, Allergy, British Columbia Children's Hospital, Research, Cell, DRS, University of British Columbia, Sol, Disease, Tissue, Mouse, Rheumatoid arthritis, Cancer, Inflammation, Asthma, FRCPC, University, JAK, Mutation, Faculty, Hypereosinophilic syndrome, Nervous system, Gene, Lung, MBBS, Neuroinflammation, Patient, JAK1, Medical school, Diagnosis, Canada Research Chair, STAT6, Signal, Pharmaceutical industry

NEW YORK, Dec. 21, 2023 /PRNewswire-PRWeb/ -- Researchers at the Icahn School of Medicine at Mount Sinai have gained a deeper understanding of the nuanced roles of JAK inhibitors, or modulators, in inflammation across various cell types and tissues. Their findings suggest a more precise approach is required to potentially expand JAK inhibitor use to a wider range of allergy and inflammatory disorders. Details on the findings were published in the December 21, 2023, issue of the journal Cell (DOI: 10.1016/j.cell.2023.11.027).

Key Points: 
  • Their findings suggest a more precise approach is required to potentially expand JAK inhibitor use to a wider range of allergy and inflammatory disorders.
  • Current JAK inhibitors work well against inflammation in diseases like eczema, but the study suggests a need for a nuanced approach in modulating JAK activity for conditions like asthma.
  • The study showed that activated JAK1 signaling has tissue-specific effects, including an unexpected immunoregulatory role in lung sensory neurons, where it suppresses lung inflammation.
  • In the lung neurons of the mice, the JAK1 mutant protein reduced inflammation caused by exposure to mold by producing substances that suppress inflammation.

Recludix Pharma Enters into a Strategic Collaboration with Sanofi to Advance Novel Oral STAT6 Inhibitor in Multiple Immunological and Inflammatory Indications

Retrieved on: 
Thursday, July 20, 2023
Partnership, Doctor of Pharmacy, Inflammation, CSO, I&I, Cancer, SH2, Patient, SAN, STAT6, Disease, Music, Pharmaceutical industry, Sanofi

SAN DIEGO, July 20, 2023 (GLOBE NEWSWIRE) -- Recludix Pharma, a leader in platform approaches to discover inhibitors of challenging targets for inflammatory disease and cancer, today announced that the company has entered into a strategic collaboration with Sanofi (NASDAQ: SNY) to develop and commercialize first-in-class oral small molecule STAT6 (signal transducer and activator of transcription 6) inhibitors for patients with immunological and inflammatory (I&I) diseases. STAT6 is believed to play a key role in multiple dermatological and respiratory diseases.

Key Points: 
  • STAT6 is believed to play a key role in multiple dermatological and respiratory diseases.
  • “This collaboration for the advancement of a preclinical oral STAT6 inhibitor speaks to our ability to successfully solve the challenge of drugging this attractive, yet elusive, therapeutic target,” said Nancy Whiting, PharmD, CEO of Recludix.
  • Under the partnership, Sanofi will have global rights to small molecule STAT6 inhibitors.
  • Recludix will advance STAT6 inhibitors from preclinical research and development until the start of Phase 2 clinical trials.

ASLAN Pharmaceuticals Announces Publication in Clinical Immunology Highlighting Eblasakimab’s Unique Mechanism of Action in the Treatment of Atopic Dermatitis

Retrieved on: 
Friday, June 23, 2023
Immunology, STAT6, AD, Atopic dermatitis, Phosphorylation, Patient, SAN, ASLN, Vaccine

The publication, titled “Eblasakimab, a novel IL-13 receptor alpha 1 monoclonal antibody, blocks STAT6 phosphorylation with low dose in human volunteers”, can be accessed here .

Key Points: 
  • The publication, titled “Eblasakimab, a novel IL-13 receptor alpha 1 monoclonal antibody, blocks STAT6 phosphorylation with low dose in human volunteers”, can be accessed here .
  • “We are excited about the publication of this data from our earlier Phase 1a study of eblasakimab in a high impact journal.
  • The results show that eblasakimab appears to completely block IL-13Rα1 and inhibit activation of STAT6 which is responsible for driving expression of many inflammatory effector molecules,” said Dr Ferda Cevikbas, Head Translational Sciences, ASLAN Pharmaceuticals.
  • “This, together with other data we have recently generated, suggests eblasakimab has the potential to be differentiated from other monoclonal antibodies acting on these pathways due to its distinct blocking of Type 2 receptor signaling without impairing Type 1 receptor signaling.”

Pusan National University Researchers Uncover Novel Gene That Regulates Leukemia Development and Progression

Retrieved on: 
Wednesday, February 1, 2023
B cell, AML, Mouse, Bone marrow, Hematological Cancer Research Investment and Education Act, Protein, Myeloid leukemia, Leukemia, ROS, Acute myeloid leukemia, Patient, Aptamer, Cell, RNA, SURF4, Research, Letter, TBK1, Cell death, STAT6, Immune system, Death, Differentiable function, Disease, Growth, Prevalence, Pusan National University, Neoplasm, Vaccine

BUSAN, South Korea, Feb. 1, 2023 /PRNewswire/ -- Leukemia, a type of blood cancer, affected around 2.3 million people around the world in 2015. Acute myeloid leukemia (AML)—a particularly aggressive disease—generally starts in the bone marrow, when stem cells cannot differentiate into white blood cells, which reduces the number of healthy blood cells in the body, leading to a very weak immune system, among other problems. Given the prevalence and implications of this disease, there has been a lot of research on the development and progression of leukemia. This has led to the discovery of a protein, stimulator of interferon genes (STING), which interacts with two other proteins—TANK-binding kinase 1 (TBK1) and signal transducer and activator of transcription 6 (STAT6)—to exert anti-cancer effects in blood cancers. Researchers have also observed that a particular gene—surfeit 4 (SURF4)—is highly expressed in leukemic cells, and its protein, SURF4, binds to STING. However, we are still unclear about how SURF4 affects the STING-TBK1-STAT6 axis, and what role it plays in leukemia. So, a team of researchers from Pusan National University, Republic of Korea set out to understand this. They were led by Professors Dongjun Lee and Yun Hak Kim, who explain the rather humanitarian motive for their research. "Children who suffer from AML relapses seldom survive. This makes studying the mechanisms of AML very important. Uncovering the effects of proteins like SURF4 may lead to new therapeutic strategies for AML, which hasn't happened in four decades". The team ran a series of experiments, the findings of which are detailed in a letter to the editor, published on 6 November 2022 in Cancer Communications.

Key Points: 
  • Given the prevalence and implications of this disease, there has been a lot of research on the development and progression of leukemia.
  • Researchers have also observed that a particular gene—surfeit 4 (SURF4)—is highly expressed in leukemic cells, and its protein, SURF4, binds to STING.
  • However, we are still unclear about how SURF4 affects the STING-TBK1-STAT6 axis, and what role it plays in leukemia.
  • So, a team of researchers from Pusan National University, Republic of Korea set out to understand this.

Codiak Presents Preclinical Data on exoASO™-STAT6 and exoASO™-C/EBPβ Programs at the Society for Immunotherapy of Cancer (SITC) 2022 Annual Meeting

Retrieved on: 
Thursday, November 10, 2022
Therapeutic index, Histology, ASO, Biology, Colorectal cancer, Tams, Exosome, HCC, STAT6, Infection, Engineering, Security (finance), MDSC, Tumor microenvironment, IL4R, U.S. Securities and Exchange Commission, Cancer, Neoplasm, Factor X, Liver, Asos, Patient, NSCLC, CEO, Glycoprotein, RNA transfection, Private Securities Litigation Reform Act, Protein, PK, Peptide, Liver disease, Mouse, Monocyte, Myelocyte, Toxicity, Pharmacology, Tropism, Phenotype, PD, Trial of the century, GLOBE, The Cancer Genome Atlas, Myeloid-derived suppressor cell, Database, Large-cell lung carcinoma, NASDAQ, TCGA, Biomarker, Tumor-associated macrophage, Therapy, SITC, Pharmaceutical industry, Vaccine, Medical imaging

CAMBRIDGE, Mass., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (NASDAQ: CDAK), a clinical-stage biopharmaceutical company pioneering the development of exosome-based therapeutics as a new class of medicines, today announced new preclinical data from its exoASO™-STAT6 and exoASO™-C/EBPβ programs. exoASO-STAT6, an engineered exosome precision medicine candidate designed to selectively deliver antisense oligonucleotides to disrupt STAT6 signaling in tumor-associated macrophages (TAMs) and induce an anti-tumor immune response, demonstrated a strong preclinical pharmacokinetic (PK) and pharmacodynamic (PD) profile in preclinical models. Codiak has also identified PD biomarkers with clinical translational potential and described a rationale for selecting cancer subtypes that could benefit from treatment with exoASO-STAT6.

Key Points: 
  • Codiak has also identified PD biomarkers with clinical translational potential and described a rationale for selecting cancer subtypes that could benefit from treatment with exoASO-STAT6.
  • Taken together, these data presented at SITC paint a compelling picture of the potential of our programs and our platform.
  • In multiple in vivo preclinical studies, exoASO-STAT6 demonstrated potent single agent activity, including >90% tumor growth inhibition and 50-80% complete responses.
  • High levels of C/EBP expression are associated with poor prognosis in multiple cancers, including non-small cell lung cancer (NSCLC).